ASCLETIS-B (01672) recommends adopting the 2025 stock option plan and 2025 stock reward plan.
Songli Pharmaceutical-B (01672) announced, in order to provide effective incentives to attract and retain valuable individuals for the company's development...
ASCLETIS-B (01672) announced that, in order to provide effective incentives to attract and retain valuable talents for the company's development, the board of directors proposed to adopt the 2025 Stock Option Plan and 2025 Stock Incentive Plan in accordance with Chapter 17 of the Listing Rules. Subject to their approval at the shareholders' extraordinary general meeting, the existing stock option plan will terminate after the adoption of the 2025 Stock Option Plan and 2025 Stock Incentive Plan.
On January 14, 2025, the board of directors resolved to grant rewards in accordance with the 2025 Stock Option Plan and 2025 Stock Incentive Plan.
Related Articles

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


